Braftovi approved in South Korea for colorectal cancer

20 August 2021

Japanese drugmaker Ono Pharmaceutical (TYO: 4525) closed up 1% today, after it announced that its Ono Pharma Korea Co unit has received marketing approval for Braftovi (encorafenib) Capsule 75mg, a BRAF inhibitor, from the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of adult patients with advanced or recurrent BRAFV600E-mutant colorectal cancer after prior therapy, in combination therapy with Eli Lilly’s (NYSE: LLY) Erbitux (cetuximab), an anti-human EGFR monoclonal antibody.

Ono Pharma acquired rights to encorafenib for Japan and South Korea in 2017 from USA-based Array BioPharma, which in 2019 was acquired by US pharma giant Pfizer (NYSE: PFE) in a deal worth over $11 billion.

Clinical backing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK